The company allegedly promoted the drug for off-label uses in children and the elderly well before establishing the drug was not effective or safe for any use by patients of those ages.
What does OLU stand for?
OLU stands for Off-Label Use (prescribed use of drug not in accordance with label of FDA approval)
This definition appears somewhat frequently and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other definitions of OLU
We have 4 other meanings of OLU in our Acronym Attic
- On-Line Traffic School, Inc. (est. 1996; Camarillo, CA)
- Optical Loss Test Set
- Organizational Level Test Set
- Outdoor Leadership Training Seminar
- On-Line Telephone Service Request
- On-Line Teller Terminal
- Optic Line Terminal Unit
- Original Loan-to-Value ratio
- Orthotopic Liver Transplantation
- Columbus, Nebraska (airport code)
- Open Learning Unit (various locations)
- Organizacion de Latinos Unidos (Spanish: United Latino Organization)
- Organization for Lukumi Unity (African diaspora religion group)
- Our Little Universe (online forum)
- Ozarks Labor Union Archives (Missouri State University)
- Online Union Catalog
- Official Land Use District (San Bernardino, CA)
- Olympia Linux Users Group
- Object Oriented Librarian User Interface Tool (software)
- Office Microlaparoscopy Under Local Anesthesia
Samples in periodicals archive:
As part of the settlement, the pharmaceutical company is admitting to promoting the drugs Paxil and Wellbutrin for off-label uses and failing to report safety data about Avandia to the Food and Drug Administration.
Other activities that could lead to 'solicited' requests about off-label use include * encouraging bloggers to write about off-label uses of a product.
At the most basic level, one may wonder why off-label use of drugs is permitted at all.
Irvine CA), the maker of Botox, agreed to pay $600 million to settle claims that it had illegally marketed the drug from 2000 to 2005 for off-label uses including headaches and cerebral palsy in children.
79) In 1997, the FDA passed section 401 of the Food and Drug Administration Modernization Act ("FDAMA"), (80) which explicitly created a safe harbor from the prohibition on marketing off-label use for journal articles.